Rare Diseases and Orphan Drugs: A comprehensive approach of strategic perspectives

ISSN： 1753-8076

Source： Journal of Communication In Healthcare, Vol.5, Iss.4, 2012-12, pp. : 199-219

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The Challenges of Orphan Drugs and Orphan Diseases: Real and Imagined

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 92, Iss. 2, 2012-08 ,pp. : 151-153

John Wiley & Sons Inc

Access to resources Recommend Favorite

The impact of new (orphan) drug approvals on premature mortality from rare diseases in the United States and France, 1999–2007

By Lichtenberg Frank

The European Journal of Health Economics, Vol. 14, Iss. 1, 2013-02 ,pp. : 41-56

Springer Publishing Company

Access to resources Recommend Favorite

Orphan Kidney Diseases

Nephron Clin Pract, Vol. 120, Iss. 4, 2012-08 ,pp. : c194-c199

Karger

Access to resources Recommend Favorite

The Role of Academic Institutions in the Development of Drugs for Rare and Neglected Diseases

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 92, Iss. 2, 2012-08 ,pp. : 193-202

John Wiley & Sons Inc

Access to resources Recommend Favorite

A comprehensive genomic approach for neuromuscular diseases gives a high diagnostic yield

ANNALS OF NEUROLOGY, Vol. 77, Iss. 2, 2015-02 ,pp. : 206-214

John Wiley & Sons Inc

Access to resources Recommend Favorite